Cadalimab is the recent innovation by Cadila Pharmaceuticals Ltd. Cadalimab, an Adalimumab biosimilar, is used to treat rheumatoid arthritis, psoriatic arthritis, Ankylosing Spondylitis and psoriasis. Adalimumab is a disease-modifying antirheumatic drug and a monoclonal antibody that works by inactivating tumor necrosis factor-alpha (TNFα) recommended in the treatment of many diseases. Adalimumab is popular under the brand name Humira® by Abbvie.

Read blogs about Psoriasis and other healthcare challenges here:

What is Psoriasis? What causes Psoriasis? – Two important questions answered